Juan Gómez Rivas, Associate Professor at Complutense University of Madrid, shared on X:
“If MRI and PSMA PET both point to prostate cancer, what would a biopsy still add before treatment?
At the Chinese Urological Congress CUA26 and SIU-Urology forum, we discussed a biopsy-free study needs to answer two different questions. How often would concordant imaging lead to treatment in men without clinically significant cancer?
And among men who do have significant cancer, how often would knowing the grade beforehand change the choice of treatment?

Two talks at the 3i Vision meeting earlier that week tackled related decisions.
In risk-adapted screening, the challenge is to use PSA, PSA density and MRI to find cancers likely to cause harm while limiting overdiagnosis.
In advanced prostate cancer, the challenge is to judge how much benefit seen in a trial is likely to carry over to a patient with different comorbidities, prior treatments or access to care.
Across all three discussions, one question tied them together. When a test or treatment changes what happens next, does it really improve what matters the most to patients?”
You can also read:
New Prostate Cancer Screening Guidelines Recommend Regular PSA Testing
